Subject(s)
Blood Coagulation Disorders/blood , Blood Platelet Disorders/blood , Diabetic Nephropathies/blood , Glomerulonephritis/blood , Glomerulosclerosis, Focal Segmental/blood , Adult , Blood Coagulation Disorders/etiology , Blood Platelet Disorders/etiology , Chronic Disease , Diabetic Nephropathies/complications , Female , Glomerulonephritis/complications , Glomerulosclerosis, Focal Segmental/complications , Hemostasis , Humans , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/complications , Male , Nephrotic Syndrome/blood , Nephrotic Syndrome/complicationsABSTRACT
3-week heparin treatment (25000 U/day) of 38 patients with diabetic glomerulosclerosis (DGS) produced positive results in 31 of them, was ineffective in 5 patients and induced complications in 2 cases. Prognostic criteria of heparin treatment efficacy basing on hemostatic changes on day 7 have been developed. Hemostasis was controlled most effectively in patients receiving heparin by a new graphic turbidimetric method capable of objective registration of clotting and fibrinolysis in one plasma portion. Because individual sensitivity to heparin widely varies and this variability manifests as early as first days of treatment, control over hemostasis system in heparin day dose 25000 U/day is advisable before treatment, on treatment day 3, 7 and on aftertreatment day 2.
Subject(s)
Diabetic Nephropathies/drug therapy , Glomerulosclerosis, Focal Segmental/drug therapy , Heparin/therapeutic use , Adult , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/blood , Drug Evaluation , Female , Glomerulosclerosis, Focal Segmental/blood , Hemostasis/drug effects , Humans , Male , Middle Aged , Prognosis , Time FactorsABSTRACT
Leukocytic dehydrogenases (succinate and alpha-glucose phosphate dehydrogenases) and acid and alkaline phosphatase hydrolases activities were cytochemically assayed in 20 healthy women with normal menstrual cycles (controls) and 34 ones with habitual abortions. Ovulation in health was associated with a significant elevation of SDH, alpha-GPDH, and alkaline phosphatase activities. The second peak of enzymic activation, less marked, was recorded on days 20-24 of the cycle. Acid phosphatase activity was reduced by the second phase of the cycle. In women with habitual abortions the activities of redox enzymes (SDH and alpha-GPDH) reduced as against the controls (p less than 0.05, less than 0.01, less than 0.001), and no ovulatory peak of enzymic activation was detectable. The curves of enzymic activities were in good correlation with rectal temperature curves of the examinees. Elevated enzymic activities during ovulation and in the second phase of a normal cycle evidenced a sufficiently high energy supply of these processes. The detected reduction of leukocytic enzymic activities in women with habitual abortions may be used for the early diagnosis of an unfavorable pregnancy course and, possibly, for the prediction of placental insufficiency.
Subject(s)
Abortion, Habitual/enzymology , Leukocytes/enzymology , Abortion, Habitual/diagnosis , Acid Phosphatase/blood , Adolescent , Alkaline Phosphatase/blood , Clinical Enzyme Tests , Female , Glucosephosphate Dehydrogenase/blood , Histocytochemistry , Humans , Pregnancy , Prognosis , Succinate Dehydrogenase/bloodABSTRACT
Indices of thrombocytic hemostasis were determined in 40 patients with diabetic glomerulosclerosis. It was found that patients suffering of diabetic glomerulosclerosis with chronic renal insufficiency showed signs of hypercoagulemia while changes of the thrombocytic hemostasis become of diverse values. There was a high correlation of hemostasis changes and clinical manifestations of diabetes mellitus and diabetic glomerulosclerosis. Three tests are recommended for treatment choice: hemolysate-aggregation test, determination of soluble complexes of monomer fibrin and fibrin-splitting product.